Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and genomic factors associated with its efficacy remain poorly characterized. Here, in a multi-institutional retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Alessi, Joao V., Ricciuti, Biagio, Wang, Xinan, Pecci, Federica, Di Federico, Alessandro, Lamberti, Giuseppe, Elkrief, Arielle, Rodig, Scott J., Lebow, Emily S., Eicholz, Jordan E., Thor, Maria, Rimner, Andreas, Schoenfeld, Adam J., Chaft, Jamie E., Johnson, Bruce E., Gomez, Daniel R., Awad, Mark M., Shaverdian, Narek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349822/
https://www.ncbi.nlm.nih.gov/pubmed/37454214
http://dx.doi.org/10.1038/s41467-023-39874-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349822/
https://www.ncbi.nlm.nih.gov/pubmed/37454214
http://dx.doi.org/10.1038/s41467-023-39874-8

Ejemplares similares